HUTCHMED (China) Limited
HCM
Cena:
Valuace
70
Růst
30
Zdraví
60
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
HCM IV ACQUISITION CORP ANNOUNCES PRICING OF $250 MILLION INITIAL PUBLIC OFFERING
11-02-2026
NORWALK, CT , FEB. 11, 2026 (GLOBE NEWSWIRE) -- HCM IV ACQUISITION CORP (THE “COMPANY”), A BLANK...
Více zde
HUTCHMED TO ANNOUNCE 2025 FINAL RESULTS
06-02-2026
HONG KONG AND SHANGHAI AND FLORHAM PARK, N.J., FEB. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (CHINA) LI...
Více zde
HOMELAND PROVIDES CLARIFICATION ON PRIOR INVESTOR RELATIONS SERVICES AGREEMENT WITH HOLDCO MARKETS
15-01-2026
VANCOUVER, BRITISH COLUMBIA--(NEWSFILE CORP. - JANUARY 15, 2026) - HOMELAND URANIUM CORP. (TSXV: HLU...
Více zde
HUTCHMED HIGHLIGHTS PUBLICATION OF PHASE III SACHI RESULTS IN THE LANCET
13-01-2026
— FIRST RANDOMIZED PHASE III TRIAL CONFIRMING THE EFFICACY OF MET INHIBITION IN PATIENTS WITH ADVA...
Více zde
BRISTOL MYERS SQUIBB ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 SCOUT-HCM TRIAL EVALUATING CAMZYOS (MAVACAMTEN) IN ADOLESCENTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
12-01-2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--BMS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHAS...
Více zde
HUTCHMED ANNOUNCES POSITIVE TOPLINE RESULTS OF PHASE III PART OF ESLIM-02 TRIAL OF SOVLEPLENIB FOR WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA IN CHINA
06-01-2026
— DELIVERS RAPID, DURABLE RESPONSES IN WAIHA, THE MORE COMMON FORM OF THIS POTENTIALLY LIFE-THREAT...
Více zde
HUTCHMED INITIATES PHASE III STAGE OF THE ONGOING TRIAL OF THE COMBINATION OF SURUFATINIB AND CAMRELIZUMAB FOR TREATMENT-NAÏVE PANCREATIC DUCTAL ADENOCARCINOMA
04-01-2026
HONG KONG AND SHANGHAI AND FLORHAM PARK, N.J., JAN. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (CHINA) LI...
Více zde
HUTCHMED ANNOUNCES NDA ACCEPTANCE IN CHINA WITH PRIORITY REVIEW STATUS FOR SAVOLITINIB FOR THE TREATMENT OF GASTRIC CANCER PATIENTS WITH MET AMPLIFICATION
30-12-2025
— NDA SUPPORTED BY POSITIVE PHASE II REGISTRATION STUDY DATA IN CHINESE PATIENTS; FOLLOWS BREAKTHR...
Více zde
HUTCHMED ANNOUNCES NDA ACCEPTANCE IN CHINA WITH PRIORITY REVIEW STATUS FOR FANREGRATINIB IN SECOND-LINE INTRAHEPATIC CHOLANGIOCARCINOMA
29-12-2025
— NDA SUPPORTED BY RESULTS FROM A PHASE II REGISTRATION TRIAL IN CHINA — — SECOND MOST COMMON...
Více zde
EDGEWISE THERAPEUTICS ANNOUNCES COMPLETION OF THE EDG-7500 CIRRUS-HCM PHASE 2 PARTS B AND C AND FAVORABLE INTERIM SAFETY RESULTS FROM THE ONGOING PART D STUDY IN HYPERTROPHIC CARDIOMYOPATHY
24-12-2025
BOULDER, COLO., DEC. 24, 2025 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC., (NASDAQ: EWTX), TODAY ANN...
Více zde
HUTCHMED INITIATES GLOBAL CLINICAL DEVELOPMENT OF ATTC CANDIDATE HMPL-A251 IN PATIENTS WITH SOLID TUMORS
16-12-2025
— FIRST-IN-HUMAN TRIAL OF CANDIDATE FROM THE NEXT-GENERATION ATTC PLATFORM — — SIMULTANEOUS CH...
Více zde
HUTCHMED HIGHLIGHTS CLINICAL DATA TO BE PRESENTED AT THE 2025 ESMO ASIA CONGRESS AND THE 2025 ASH ANNUAL MEETING
26-11-2025
HONG KONG AND SHANGHAI AND FLORHAM PARK, N.J., NOV. 27, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (CHINA) LI...
Více zde
HUTCHMED HIGHLIGHTS PIPELINE AND BUSINESS PROGRESS AT R&D UPDATES EVENT
02-11-2025
— HUTCHMED UNVEILS ITS INNOVATIVE ATTC PLATFORM, POTENTIALLY PROVIDING PRECISION ONCOLOGY WITH SYN...
Více zde
TERRESTRIAL ENERGY INC. COMPLETES BUSINESS COMBINATION WITH HCM II ACQUISITION CORP.
28-10-2025
TERRESTRIAL ENERGY TO BEGIN TRADING ON THE NASDAQ STOCK MARKET UNDER TICKER SYMBOL “IMSR” ON OCT...
Více zde
HCM II ACQUISITION CORP. SHAREHOLDERS APPROVE BUSINESS COMBINATION WITH TERRESTRIAL ENERGY
20-10-2025
CHARLOTTE, N.C. AND STAMFORD, CONN., OCT. 20, 2025 (GLOBE NEWSWIRE) -- HCM II ACQUISITION CORP. (NAS...
Více zde
HUTCHMED ANNOUNCES APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF BOARD COMMITTEE
14-10-2025
HONG KONG AND SHANGHAI AND FLORHAM PARK, N.J., OCT. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (CHINA) LI...
Více zde
HUTCHMED HIGHLIGHTS FRUSICA-2 REGISTRATION TRIAL DATA TO BE PRESENTED AT THE 2025 ESMO CONGRESS
13-10-2025
THE FRUQUINTINIB AND SINTILIMAB COMBINATION DEMONSTRATED SIGNIFICANT PFS IMPROVEMENTS IN ADVANCED RE...
Více zde
INFOSYS COLLABORATES WITH TELENOR SHARED SERVICES TO MODERNIZE ITS HR OPERATIONS WITH A NEW ORACLE FUSION CLOUD HUMAN CAPITAL MANAGEMENT (HCM) SOLUTION
03-10-2025
AIMS TO STANDARDIZE HR PROCESSES, ENHANCE EMPLOYEE PRODUCTIVITY AND EXPERIENCE BENGALURU, INDIA , OC...
Více zde
HUTCHMED HIGHLIGHTS CLINICAL DATA TO BE PRESENTED AT THE ESMO CONGRESS 2025
01-10-2025
HONG KONG AND SHANGHAI AND FLORHAM PARK, N.J., OCT. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (CHINA) LI...
Více zde
HCM II ACQUISITION CORP. AND TERRESTRIAL ENERGY ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT AND OCTOBER 20, 2025 EXTRAORDINARY GENERAL MEETING OF HCM II SHAREHOLDERS TO APPROVE BUSINESS COMBINATION
29-09-2025
CHARLOTTE, N.C. & STAMFORD, CONN.--(BUSINESS WIRE)--HCM II ACQUISITION CORP. (NASDAQ: HOND) (“HCM ...
Více zde
HCM III ACQUISITION CORP. ANNOUNCES THE SEPARATE TRADING OF ITS CLASS A ORDINARY SHARES AND WARRANTS, COMMENCING SEPTEMBER 22, 2025
19-09-2025
STAMFORD, CT, SEPT. 19, 2025 (GLOBE NEWSWIRE) -- HCM III ACQUISITION CORP. (NASDAQ: HCMAU) (THE “C...
Více zde
SAVE THE DATE: HUTCHMED TO PRESENT R&D UPDATES ON OCTOBER 31, 2025
11-09-2025
— HUTCHMED WILL HOST IN-PERSON PRESENTATION AND ONLINE WEBINAR ON FRIDAY, OCTOBER 31 — — HUTCH...
Více zde
HUTCHMED HIGHLIGHTS CLINICAL DATA TO BE PRESENTED AT THE 2025 WORLD CONFERENCE OF LUNG CANCER AND THE CSCO ANNUAL MEETING 2025
04-09-2025
HONG KONG AND SHANGHAI AND FLORHAM PARK, N.J., SEPT. 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (CHINA) L...
Více zde
TENAYA THERAPEUTICS PRESENTS INTERIM DATA FROM MYCLIMB™ NATURAL HISTORY STUDY OF MYBPC3-ASSOCIATED HCM PEDIATRIC PATIENTS AT EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2025
31-08-2025
LARGEST NONINTERVENTIONAL NATURAL HISTORY STUDY OF PEOPLE UNDER 18 WITH MYBPC3-ASSOCIATED HCM WITH M...
Více zde
HUTCHMED ANNOUNCES APPOINTMENT OF ACTING CHIEF EXECUTIVE OFFICER
24-08-2025
HONG KONG AND SHANGHAI AND FLORHAM PARK, N.J, AUG. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (CHINA) LIM...
Více zde
HUTCHMED COMPLETES PATIENT ENROLLMENT OF SANOVO PHASE III TRIAL OF ORPATHYS® AND TAGRISSO® COMBINATION AS A FIRST-LINE THERAPY FOR CERTAIN LUNG CANCER PATIENTS IN CHINA
19-08-2025
HONG KONG AND SHANGHAI AND FLORHAM PARK, N.J., AUG. 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (CHINA) LI...
Více zde
HCM III ACQUISITION CORP ANNOUNCES CLOSING OF $253,000,000 INITIAL PUBLIC OFFERING
04-08-2025
STAMFORD, CT, AUG. 04, 2025 (GLOBE NEWSWIRE) -- HCM III ACQUISITION CORP (NASDAQ: HCMAU) (THE “COM...
Více zde
HCM III ACQUISITION CORP. ANNOUNCES PRICING OF $220 MILLION INITIAL PUBLIC OFFERING
31-07-2025
STAMFORD, CT, JULY 31, 2025 (GLOBE NEWSWIRE) -- HCM III ACQUISITION CORP. (THE “COMPANY”), A BLA...
Více zde
HUTCHMED TO ANNOUNCE 2025 HALF-YEAR FINANCIAL RESULTS
03-07-2025
HONG KONG AND SHANGHAI AND FLORHAM PARK, N.J., JULY 03, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (CHINA) LI...
Více zde
HUTCHMED ANNOUNCES CHINA APPROVAL FOR ORPATHYS® IN COMBINATION WITH TAGRISSO® FOR THE TREATMENT OF LUNG CANCER PATIENTS WITH MET AMPLIFICATION AFTER PROGRESSION ON FIRST-LINE EGFR INHIBITOR THERAPY
30-06-2025
— APPROVAL BASED ON PHASE III SACHI TRIAL RESULTS WHICH SHOWED A 66% REDUCED RISK OF PROGRESSION ...
Více zde
Dokumenty nejsou k dispozici
